Joanna L Whitehouse
Overview
Explore the profile of Joanna L Whitehouse including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
274
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Choyce J, Hewison A, Swift A, Whitehouse J
Chron Respir Dis
. 2025 Jan;
22:14799731241249476.
PMID: 39876815
The use of non-invasive ventilation (NIV) in patients with advanced cystic fibrosis (CF) has increased in recent years. Research evidence supports its clinical benefits, but less is known about the...
2.
Desai M, Hine C, Whitehouse J, Brownlee K, Charman S, Nagakumar P
Respir Med
. 2022 May;
199:106878.
PMID: 35633605
Background: The availability of mutation-specific cystic fibrosis modulator therapies has the potential to improve the lives of children and adults with cystic fibrosis. The frequency of mutations causing defects in...
3.
Nash E, Choyce J, Carrolan V, Justice E, Shaw K, Sitch A, et al.
Ther Adv Respir Dis
. 2022 Mar;
16:17534666211070133.
PMID: 35274585
Background: Home monitoring (HM) is able to detect more pulmonary exacerbations (PEx) than routine care (RC) in individuals with cystic fibrosis (CF), but there is currently no evidence for benefits...
4.
Kempegowda P, Sunsoa H, Chandan J, Quinn L, Amrelia P, Atta S, et al.
Ther Adv Endocrinol Metab
. 2022 Feb;
11:2042018820966428.
PMID: 35154634
Aims: To study the prevalence of microvascular complications and renal changes associated with cystic fibrosis-related diabetes (CFRD). Methods: This retrospective cohort study was conducted at the West Midlands Adult Cystic...
5.
Webb K, Zain N, Stewart I, Fogarty A, Nash E, Whitehouse J, et al.
J Med Microbiol
. 2022 Feb;
71(2).
PMID: 35113780
Although anaerobic bacteria exist in abundance in cystic fibrosis (CF) airways, their role in disease progression is poorly understood. We hypothesized that the presence and relative abundance of the most...
6.
Barrett J, Slatter G, Whitehouse J, Nash E
J Hum Nutr Diet
. 2021 Dec;
35(5):757-764.
PMID: 34914145
Background: Cystic fibrosis (CF) is a multisystem disorder that primarily affects the respiratory and gastrointestinal systems. Dietetic therapy is a prominent aspect of CF management, with patients receiving nutritional surveillance...
7.
Zain N, Webb K, Stewart I, Halliday N, Barrett D, Nash E, et al.
J Med Microbiol
. 2021 Oct;
70(10).
PMID: 34596013
produces quorum sensing signalling molecules including 2-alkyl-4-quinolones (AQs), which regulate virulence factor production in the cystic fibrosis (CF) airways. Culture can lead to condition-dependent artefacts which may limit the potential...
8.
Webb K, Camara M, Zain N, Halliday N, Bruce K, Nash E, et al.
J Cyst Fibros
. 2021 Sep;
21(4):626-629.
PMID: 34518117
Pseudomonas aeruginosa produces specific signalling molecules, 2-alkyl-4-quinolones (AQs) that are detectable in the sputum of adults with cystic fibrosis (CF) and who have pulmonary infection with this opportunistic pathogen. This...
9.
Webb K, Fogarty A, Barrett D, Nash E, Whitehouse J, Smyth A, et al.
J Med Microbiol
. 2019 Nov;
68(12):1823-1828.
PMID: 31671047
is an important respiratory pathogen in cystic fibrosis (CF), which is associated with an accelerated decline in lung function, frequent pulmonary exacerbations and increased mortality. produces intercellular signalling molecules including...
10.
Boyle M, Moore J, Whitehouse J, Bilton D, Downey D
Mycopathologia
. 2018 Mar;
183(4):723-729.
PMID: 29500636
There is much uncertainty as to how fungal disease is diagnosed and characterized in patients with cystic fibrosis (CF). A 19-question anonymous electronic questionnaire was developed and distributed to ascertain...